ストックスクリーナーアプリを入手
11.34
3.18%
0.35
前日終値:
$10.99
開ける：
$11.13
24時間の取引高:
349.45K
Relative Volume:
0.80
時価総額：
$223.60M
収益：
$244.06M
当期純損益:
$87.01M
株価収益率:
6.2263
EPS:
1.8213
ネットキャッシュフロー:
$105.95M
1週間 パフォーマンス:
+3.56%
1か月 パフォーマンス:
-25.49%
6か月 パフォーマンス:
-28.23%
1年 パフォーマンス:
+0.44%
1日の値動き範囲:
$11.13
$11.41
1週間の範囲:
$10.57
$11.41
52週間の値動き範囲:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.34 | 223.60M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Fed Meeting: What are Keros Therapeutics Incs technical support levels2026 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn
Chart Watch: What is Keros Therapeutics Incs P E ratio telling us2026 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Institution Moves: Can Keros Therapeutics Inc weather a recessionM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Published on: 2026-03-25 15:00:50 - baoquankhu1.vn
KROS stock: What to know about Rinvatercept in DMD - MSN
KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart.com
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - Stock Traders Daily
Quarterly Trades: Is now the right time to enter Keros Therapeutics Inc2026 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Block Trades: Will RIVN benefit from current market trendsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept stand out in the DMD market? - MSN
Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
KROS: Does the Discounted Book Value Represent a Value Trap? - Bitget
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - sharewise.com
KROS Stock: Key Information on Rinvatercept for DMD - Bitget
KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget
KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance
KROS PE Ratio & Valuation, Is KROS Overvalued - Intellectia AI
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart
Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com
Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan
Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan - Stock Titan
Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily
Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL) - The Globe and Mail
Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart
Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times
Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView
Keros (NASDAQ: KROS) moves rinvatercept toward Phase 2 in ALS, DMD - Stock Titan
Keros Therapeutics Presents Additional Clinical Data from - GlobeNewswire
Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat
Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn
Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir
Keros Therapeutics, Inc. (KROS) reports Q4 loss, misses revenue estimates - MSN
Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget
What is HC Wainwright's Estimate for KROS FY2030 Earnings? - MarketBeat
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility - TipRanks
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat
Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):